beta
/Characteristics of OFF-time Improvement in a Phase Two Study for Parkinson’s Disease (PD) with Solengepras, a Novel GPR6-inhibitor (P8-17.006)
Abstract

Abstract N/A

CitationsView All
Citing-
Cited By-